"There is competition out there for BioCryst. The government said it has ordered intravenous versions of competing drugs Tamiflu and Relenza -- 10,000 of each. Both drugs are sold by behemoths -- Tamiflu is marketed by Roche, which has annual revenue of almost $20 billion; Relenza marketer GlaxoSmithKline takes in almost twice that."
BTA Price at posting:
$2.68 Sentiment: ST Buy Disclosure: Held
